Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 May 2023 | Story Leonie Bolleurs | Photo Supplied
Spineless Cactus
Axel Tarrisse (far left), a PhD student in the Department of Sustainable Food Systems, working on the biogas and fodder potential of spineless cactus in Africa. Pictured with him are Prof Maryna de Wit, his supervisor and Associate Professor in the UFS Department of Sustainable Food Systems and Development, and Dr Herman Fouché from the Agricultural Research Council.

The spineless cactus is a unique perennial plant that is able to yield close to 40 tons of dry matter per hectare per year with a rainfall of 500 mm per annum. “This equates eight tons of biomethane or 11 000 litres of diesel-equivalent energy per hectare,” says Axel Tarrisse, a PhD student in the Department of Sustainable Food Systems and Development at the University of the Free State (UFS), who is working on the biogas and fodder potential of spineless cactus in Africa.

Tarrisse believes biogas, produced from the spineless cactus, has the potential to complement the supply of South Africa’s existing industrial energy companies to produce sustainable jet fuel and diesel and a variety of other products with the gas-to-liquid process they use.

Developing biogas

He says with rainfall, key nutrients, carbon dioxide, and solar energy it is possible to produce biomass from cactus.

“First, we harvest the cactus and macerate it prior to going into an anaerobic digester where it is heated to 38°C, the same as a cow’s body temperature. Inside the digester, naturally occurring bacteria, similar to those found in their stomachs, break down the cactus, resulting in the production of biogas. This biogas is composed of both methane and carbon dioxide,” he explains.

According to him, biogas generated through this process can be used in a number of ways. This includes running generators to produce electricity or burning it to generate heat. It will also serve as a feedstock to replace coal and natural gas used by companies such as PetroSA and Sasol in their production of synthetic renewable fuels.

“The methane can also be separated from the carbon dioxide and compressed into bottles, creating compressed biomethane. This can be used as a replacement for liquid petroleum gas (LPG), as well as petrol and diesel in vehicles, such as bakkies, tractors, buses, and delivery trucks.”

The carbon dioxide produced in the process can, for example, be used to replace the fossil-based carbon dioxide typically used in the production of carbonated beverages. Additionally, it can be applied to extend the shelf life of packaged foods, serve as a water softener, and even be applied to a variety of industrial applications.

Commercialisation 

Biogas/biomethane is already produced in Mexico on a commercial scale. In Northeast Brazil, farmers have planted 600 000 hectares of spineless cactus, also known as Palma Forrageira, but the machinery needed to harvest it only became commercially available this year.

Back home in South Africa, just 30 km outside of Bloemfontein, Barren Energy farm is at Stage 1 with 140 hectares of high-density cactus planted to provide the initial feedstock for anaerobic digestion. With 600 hectares, they will be able to produce five million litres of diesel-equivalent methane.

Tarrisse says, “With the right methodology and management system, producing biogas from the spineless cactus will be adopted relatively quickly on a commercial scale.”

He believes that the lack of investment in cultivating the spineless cactus as a crop for fodder in South Africa may be due to a few factors. “It is easier to stick to what is known, such as irrigating lucerne and maize and managing these crops with existing planters, pest management solutions, and harvesting machinery than to develop local machinery and management solutions for a perfectly adapted crop,” he says. 

Compelling reasons

According to Tarrisse, there are several compelling reasons to consider the spineless cactus as a source of biogas in South Africa.

Firstly, he explains, “Only the cactus pads, harvested from high-density plantations (20 000 plants per hectares), are used for biogas production.”

“Secondly, the spineless cactus can yield large volumes of biomass from marginal semi-arid land where conditions are unsuitable for conventional crop cultivation. This makes it an ideal option for the 65% of South African land that receives less than 500 mm of rainfall annually.”

Thirdly, he says, “The plant contains 30 to 50% of easily digestible sugars, which degrades easily in an anaerobic digester. This simple, low-tech process can provide a substantial amount of baseload energy with relatively limited capital expenditure, which is particularly important in developing countries such as South Africa where capital is difficult to raise.”

“On top of that, anaerobic digestion only extracts carbon, oxygen, and hydrogen molecules from the cactus, while most of the macro- and micronutrients, water, and some fibres remain in the digestate. This nutrient-rich cactus digestate can then be spread on the cactus fields, reducing the need for fertiliser once the plantation has been fertilised in the first two years of implementation.”

Societal impact

Besides the benefits of producing biogas from the cactus plant, there is also the opportunity of job creation. “This farming can create one million direct job opportunities from only 3% of South Africa’s land area, approximately 4 million hectares,” says Tarrisse.

He is of the opinion that if production was at scale, as opposed to the current small orchard-style farming of cactus, there would be substantial biomass available to sustain not only biomethane, but also to support various bio-industries, such as protein production through cactus fermentation, biomaterials as a substitute for wood-based cellulose, organic acids, and bioplastics. “Consequently, cactus provides a climate-resilient, drought-resistant, and perennial feedstock for food, feed, fibre, and fuel in semi-arid Southern Africa,” he says.

Tarrisse states that this initiative also has the potential to significantly reduce migration from rural to urban areas, therefore addressing issues related to the growth of urbanisation, such as the provision of infrastructure and crime.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept